http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2585806-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
filingDate | 2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77f6aa684d1403140282f4510e9912f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28925ff762fd015707d97c3fddc59b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7457583db0f8121c7d08772a8d1a08e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_593d633d232b25964b79a59384332ef5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6391f235dd35c6752256a0e80785d077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef238b1f39eda0d629b850a3576260fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bb915420884637ecf5300f62695c250 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed13a79314141925406eb58d465c5404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a04d0861effb64ea113914b935aa565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b66dfba928f3bef7acf273fdca3f67a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa2628388ad7c78b4af4e63d06c76d13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76001591dad77ddb793e6f627616ce5f |
publicationDate | 2016-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2585806-T3 |
titleOfInvention | Octahydropyrrolo [3,4-c] disubstituted pyrroles as orexin receptor modulators |
abstract | A chemical entity that is a compound of the formula (I): ** Formula ** Where: R1 is a member selected from the group consisting of: A) A phenyl substituted or unsubstituted with 1 or 2 Ra members and substituted in the ortho position with Rb; Ra is independently selected from a group consisting of -H, halo, -C1-4alkyl, -C14alkoxy, and -NO2, where 2 adjacent Ra members could join to form a 6-membered aromatic ring; Rb is a member selected from the group consisting of: a) halo, -C1-4alkoxy, -C1-4alkyl, -CF3, -OCF3, or -CN; b) a 5-membered heteroaryl ring containing among its members an oxygen or a sulfur; c) a 5-6 membered heteroaryl ring containing 1, 2 or 3 nitrogenous members, optionally containing an oxygen member, substituted or unsubstituted with halo or -C1-4alkyl; and d) a halo substituted or unsubstituted phenyl, -CH3, or -CF3; B) a pyridine substituted or unsubstituted with 1 or 2 Re members and substituted with Rd, where Rd is adjacent to the adhesion point of R1; Re is C1-4alkyl; Rd is a member selected from a group consisting of: a) A 5-6 membered heteroaryl ring selected from a group consisting of: 1H-1,2,3-triazol-1-yl, 2H-1,2, 3-triazol-2-yl, 1H-pyrazol-5-yl, 3-methyl-1,2,4-oxadiazol-5-yl, pyridinyl, 3-methyl pyridine-2-yl; 1- (tetrahydro-2H-pyrano-2-yl) -1H-pyrazol-5-yl), phenyl, and pyrimidine-2-yl; and b) -CF3, -Br, and -C1-4alkoxy; C) A heteroaryl ring of members selected from a group consisting of: 2-methyl-1,3-thiazol-yl, 1-pyrazol-5-yl, oxazol, isoxazolyl, thiophene-2-yl, and furan-2-yl, each substituted with a substituted or unsubstituted phenyl, -F; and D) a 5-13 membered aryl or heteroaryl ring selected from a group consisting of: 3-methylfuran-2-yl, 9H-fluorene, quinoline, cinoline; 3- (1H-Pyrrol-1-yl) thiophene-2-yl, 8- [1,2,3] -triazol-2-yl-naphthalene-1-yl, 2,3-dihydro-1,4-benzodioxine -5-yl, 1H-indole-7-yl, 4-fluoronaphthalene-1-yl, and naphthalen-1-yl; R2 is a member selected from the group consisting of: A) a 6-membered heteroaryl ring containing 2 nitrogenous members substituted with one or more members independently selected from a group consisting of: halo, -C1-4alkyl, -CD3, -D, -C1- 4alkoxy, cyclopropyl, morpholine-2-yl, -CO2C1-4alkyl, -CO2H, -CH2OH, -C (O) N (C1-4alkyl) 2, -CF3, -CN, -OH, - NO2, -N (C1-4alkyl) 2, phenyl, furan-2-yl, thiophene-2-yl, 1H-pyrazol-4-yl, and pyrrolidine-1-yl; B) pyridine substituted with 1 or 2 members independently selected from a group consisting of: halo, -C1-4alkyl, -C1-4alkoxy, and -CF3; C) a 9-membered heteroaryl ring selected from the group consisting of benzooxazol-2-yl, 6-fluoro-1,3-benzothiazole, 1,3-benzothiazole, 6-methoxy-1,3-benzothiazole, 6-methyl- 1,3-benzothiazole, 6-chloro-benzothiazol-2-yl, and 4-methyl-6,7-dihydro-5H-cyclopenta [d] pyrimidine; D) a 10-membered heteroaryl ring selected from a group consisting of quinoxaline-2-yl, 3- methylquinoxaline-2-yl, 6,7-difluoroquinoxaline-2-yl, 3- (trifluoromethyl) quinoxaline, quinoline, 4- methylquinoline, and 6-fluoroquinazolin-2-yl; and E) 4-methyl-1,3,5-triazine-2-yl or 2-methylpyrimidine-4 (3H) -one; and pharmaceutically acceptable salts of the compounds of the formula (I). |
priorityDate | 2009-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1694.